Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Thoracic 5Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1NET 1Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Lung Neoplasms 1Carcinoma, Large Cell 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Paclitaxel × Endocrine × Clear all
NCT01317615 2016-03-30

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Novartis

Phase 4 Completed
49 enrolled 11 charts
EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Large Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡